PHOTO: Rise In Birth Defects

Orphan disease incidence

Other Contributors: Harvard University-MIT Division of Health Sciences and Technology.

Advisor: Jeff Behrens and Isaac Kohane.

Department:

Understanding the true incidence and prevalence of a disease has tremendous value for the biopharmaceutical industry, particularly for orphan diseases that affect a minority of the population (in the US, the definition of orphan disease is a disorder that must affect less than 200, 000 people, or 1 in 1, 500). However, incidence and prevalence data for orphan diseases in scientific literature is poorly studied, inconsistent, numbers range widely and articles often contain poorly supported citations. Additionally, once a treatment is available and disease awareness increases, there may be an increase in reported disease prevalence, as patients proactively seek treatment from their healthcare providers. The goal of this research is to investigate the incidence of X-linked Hypohidrotic Ectodermal Dysplasia (XLHED) and provide a framework for investigators to study the incidence and prevalence of other rare diseases. Specific research objectives include: 1) Develop a clinical phenotype to identify XLHED patients in medical records and/or claims data 2) Analyze patient registry data to identify characteristics that are unique to XLHED and distinguish XLHED from other ectodermal dysplasias 3) Develop a robust search algorithm to accurately identify XLHED patients in claims databases By performing a thorough literature review, and an analysis of the National Foundation for Ectodermal Dysplasias (NFED) patient registry, I was able to meet the first two research objectives. After analyzing the medical record and claims data at two major academic medical centers, we were only able to identify 25 total patients, 19 of whom had associated claims data, to include in our patient cohort. Since this number was too small of a base from which to develop an identification algorithm as originally planned, I instead analyzed descriptive statistics of their claims data in order to better understand how these patients flow through the healthcare system, and what identification criteria might be valuable for an investigator studying a larger patient population in the future. Further studies using different combinations of claims and/or narrative data to more accurately identify...

You might also like
Cystic Fibrosis successfully treated by Regenocyte with
Cystic Fibrosis successfully treated by Regenocyte with ...
Exceeding Expectations with Cystic Fibrosis
Exceeding Expectations with Cystic Fibrosis
This is Cystic Fibrosis
This is Cystic Fibrosis
Cystic Fibrosis Foundation: Lewis Black Auction Promo 2013
Cystic Fibrosis Foundation: Lewis Black Auction Promo 2013
Cystic Fibrosis Pulmonary Disease
Cystic Fibrosis Pulmonary Disease
2014 Cystic Fibrosis Foundation Video
2014 Cystic Fibrosis Foundation Video
Finding a cure: incentivizing partnerships between disease advocacy groups and academic commercial researchers.: An article from: Journal of Law and Health
Book (Cleveland Marshall College of Law)

Popular Q&A

avatar
What is the difference between an Orphan Disease and a Rare Disease? - Quora

An orphan disease is a regulatory definition of a rare disease so it gets different regulatory treatment

Related Posts